Hemophilia Market to Reach Valuation of USD 14.2 Billion By 2028 - Increasing Focus on Prophylactic Treatment and Increasing Consumer Healthcare Expenditure to Flourish Market

Vantage Market Research

Jan 30, 2022

In terms of revenue, the Global Hemophilia Market is expected to reach USD 14.2 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 5.3% from 2022 to 2028. The Global Hemophilia Market growth is attributed to the factors such as, increasing focus on prophylactic treatment, increasing consumer healthcare expenditure, and rising popularity of gene therapy. Additionally, factors such as increasing investment in R&D and increasing approval of drugs for treatment of hemophilia are further fueling the market growth.

Key Findings:

  • The type A sub-segment is anticipated to grow at a substantial CAGR. The growth is attributed to the high occurrence of type A. In 2019, according to WebMD LLC, around 50-60% of patients were suffering from severe hemophilia A.
  • On-demand sub-segment held a significant market share in 2021 of treatment segment for Hemophilia Market. However, the prophylaxis sub-segment is anticipated to grow at the fastest CAGR over the forecast period as a consequence of the wide acceptance of treatment among the patients.
  • North America is the largest regional segment. This is due to rising prevalence coupled with a growing inclination towards prophylaxis treatment. The U.S. is anticipated to dominate the region owing to the presence of a large base of the population suffering from hemophilia.

Some of the key players in the Hemophilia Market include - Shire (Baxalta); CSL Behring; Pfizer, Inc.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Novo Nordisk A/S.; and Octapharma AG.

According to the Centers for Disease Control and Prevention (CDC), around 30,000 and 33,000 males are living with hemophilia in the United States. The estimated prevalence of hemophilia in the United States is 12 cases per 100,000 U.S. males for hemophilia A and 3.7 cases per 100,000 U.S. males for hemophilia B. According to the estimates, among all births in the U.S., 1 birth per 5,617 male births for hemophilia A and 1 birth per 19,283 male births for hemophilia B. thus rising number of populations suffering from hemophilia is further boosting the Hemophilia Market growth.

Additionally, increasing Research and Developments (R&D) initiatives especially on identifying therapeutic agents is further propelling the Hemophilia Market growth. Moreover, increasing consumer healthcare expenditure, and the rising popularity of gene therapy is further fueling the Hemophilia Market growth over the forecast period.

North America is the largest regional segment. The market growth is attributed to the presence of major players in the region. Also, increasing government initiatives and support in the region is further likely to propel market growth.